ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,083.57
0.36%
Dow Jones
44,747.63
-0.28%
US Dollar vs MXN
20.4967
0.19%
Brent Oil
74.845
0.92%
Bitcoin
97,438.52
0.89%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Adicet Bio Inc (ACET)

  7. Adicet Bio Inc (ACET) Noticias

Adicet Bio Inc

Adicet Bio Inc (ACET)

NASDAQ
1.03
0.02
(1.98%)
Cerrado 06 Febrero 3:00PM
Delayed by 15 minutes
1.07
0.04
( 3.88% )
Pre Mercado: 4:14AM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

ACET Noticias

Solo noticias oficiales

Form 8-K - Current report
Edgar (US Regulatory)
05 Febrero 2025
ACET (1.98%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Febrero 2025
ACET (1.98%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Febrero 2025
ACET (1.98%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
28 Enero 2025
ACET (1.98%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
23 Enero 2025
ACET (1.98%)

Form 8-K - Current report
Edgar (US Regulatory)
19 Diciembre 2024
ACET (1.98%)

Form 8-K - Current report
Edgar (US Regulatory)
27 Noviembre 2024
ACET (1.98%)

ACET Discussion

Ver más
weedtrader420 weedtrader420 2 días hace
ACET☝️🤑☝️
👍️0
glenn1919 glenn1919 2 días hace
ACET......................................https://stockcharts.com/h-sc/ui?s=ACET&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 2 días hace
ACET: Fast Track this, & Fast Track that.
👍️0
Monksdream Monksdream 5 meses hace
ACET under $2
👍️0
Monksdream Monksdream 7 meses hace
ACET under $2
👍️0
Monksdream Monksdream 7 meses hace
ACET under $2
👍️0
Monksdream Monksdream 7 meses hace
ACET new 52 week low
👍️0
glenn1919 glenn1919 7 meses hace
ACET..............................https://stockcharts.com/h-sc/ui?s=ACET&p=W&b=5&g=0&id=p86431144783
👍️0
JoseyWales88 JoseyWales88 8 meses hace
HC Wainwright and Co reiterates BUY on ACET with a $10.00 price target


HC Wainwright and Co reiterates BUY on ACET with a $10.00 price target

👍️0
Mr. Zen Mr. Zen 8 meses hace
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.

“The FDA’s decision to grant ADI-001 Fast Track Designation for lupus nephritis underscores the urgent need for new therapies for this chronic disease,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “We plan to initiate our Phase 1 clinical study in lupus nephritis later this month. With clinical data for ADI-001 in non-Hodgkin’s lymphoma demonstrating CD19+ B-cell depletion that mirrors data by autologous alpha-beta CAR T in academic clinical studies in several autoimmune diseases, we believe we are well positioned to expand our autoimmune program to address additional indications beyond lupus nephritis. We look forward to providing a comprehensive update on our autoimmune program to investors in the near term.”

Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
👍️ 1
glenn1919 glenn1919 9 meses hace
ACET....................................https://stockcharts.com/h-sc/ui?s=ACET&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 año hace
ACET new 52 week low
👍️0
Monksdream Monksdream 1 año hace
ACET new 52 week
👍️0
Monksdream Monksdream 1 año hace
ACET new 52 week low
👍️0
jondoeuk jondoeuk 1 año hace
Upcoming https://www.businesswire.com/news/home/20230927031162/en/Adicet-Bio-to-Present-Three-Scientific-Posters-Highlighting-its-Allogeneic-Gamma-Delta-T-Cell-Platform-and-Programs-at-the-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting
👍️0
jondoeuk jondoeuk 2 años hace
https://twitter.com/JacobPlieth/status/1673585690716565504
👍️0
masterofdisaster masterofdisaster 3 años hace
No sell off...guess I bet wrong
👍️0
TheFinalCD TheFinalCD 3 años hace
Phase 1's usually suck wind, I lost $80K on another one,

BIG lesson learned


👍️0
masterofdisaster masterofdisaster 3 años hace
It was weird....I think the MMs drop this at open to begin the sell off today.
👍️0
TheFinalCD TheFinalCD 3 años hace
whats weird is the rally after the offering


this market is upside down

topsy turvey

👍️0
masterofdisaster masterofdisaster 3 años hace
Bought puts today anticipating an offering and there it is.
👍️0
TheFinalCD TheFinalCD 3 años hace
13.20 low start

ACET
👍️0
crudeoil24 crudeoil24 3 años hace
14.20 in AH. Nice day for the clinical FDA phase I trial results.
👍️0
TheFinalCD TheFinalCD 3 años hace
thanks for creating the board

I was too lazy, did I say lazy, I meant bizy

https://ih.advfn.com/stock-market/NASDAQ/adicet-bio-ACET/stock-news/86734727/adicet-posts-early-stage-data-for-off-the-shelf-ca
👍️0
crudeoil24 crudeoil24 3 años hace
Adicet Bio shares are trading higher after the company announced interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001.
👍️0
crudeoil24 crudeoil24 3 años hace
Adicet Bio Inc. is a biotechnology company that is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The Company is focused on developing ADI-00x for solid tumors and hematological indications.
👍️0

Su Consulta Reciente

NASDAQ
ACET
Adicet Bio
BIT
1MC
Lvmh Moet Hennessy Louis...
USOTC
WSNAF
Wesana Health (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios